

Louise J Barber

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2043232/publications.pdf>

Version: 2024-02-01

31
papers

2,903
citations

279798

23
h-index

477307

29
g-index

35
all docs

35
docs citations

35
times ranked

4995
citing authors

#	ARTICLE	IF	CITATIONS
1	RTEL1 Maintains Genomic Stability by Suppressing Homologous Recombination. <i>Cell</i> , 2008, 135, 261-271.	28.9	315
2	Secondary mutations in <i>BRCA2</i> associated with clinical resistance to a PARP inhibitor. <i>Journal of Pathology</i> , 2013, 229, 422-429.	4.5	287
3	Cancer Evolution and the Limits of Predictability in Precision Cancer Medicine. <i>Trends in Cancer</i> , 2016, 2, 49-63.	7.4	222
4	A Critical Role for the Ubiquitin-Conjugating Enzyme Ubc13 in Initiating Homologous Recombination. <i>Molecular Cell</i> , 2007, 25, 663-675.	9.7	210
5	FANCI is a Structure-specific DNA Helicase Associated with the Maintenance of Genomic G/C Tracts. <i>Journal of Biological Chemistry</i> , 2008, 283, 36132-36139.	3.4	207
6	Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. <i>Cancer Cell</i> , 2019, 36, 35-50.e9.	16.8	179
7	Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene <i>MSH2</i> . <i>EMBO Molecular Medicine</i> , 2009, 1, 323-337.	6.9	154
8	Efficacy of Chemotherapy in <i>BRCA1/2</i> Mutation Carrier Ovarian Cancer in the Setting of PARP Inhibitor Resistance: A Multi-Institutional Study. <i>Clinical Cancer Research</i> , 2013, 19, 5485-5493.	7.0	126
9	Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment. , 2019, 7, 309.		112
10	HCLK2 is essential for the mammalian S-phase checkpoint and impacts on Chk1 stability. <i>Nature Cell Biology</i> , 2007, 9, 391-401.	10.3	111
11	Inhibitors of the Proteasome Suppress Homologous DNA Recombination in Mammalian Cells. <i>Cancer Research</i> , 2007, 67, 8536-8543.	0.9	105
12	DOG-1 Is the <i>Caenorhabditis elegans</i> BRIP1/FANCI Homologue and Functions in Interstrand Cross-Link Repair. <i>Molecular and Cellular Biology</i> , 2008, 28, 1470-1479.	2.3	99
13	Replication blocking lesions present a unique substrate for homologous recombination. <i>EMBO Journal</i> , 2007, 26, 3384-3396.	7.8	77
14	DNA Interstrand Cross-Link Repair in the <i>Saccharomyces cerevisiae</i> Cell Cycle: Overlapping Roles for PSO2 (SNM1) with MutS Factors and EXO1 during S Phase. <i>Molecular and Cellular Biology</i> , 2005, 25, 2297-2309.	2.3	68
15	CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibatamab (CEA-TCB) in patient-derived colorectal cancer organoids. , 2019, 7, 101.		65
16	Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. <i>Annals of Oncology</i> , 2013, 24, 1416-1418.	1.2	62
17	<i>C. elegans</i> FANCD2 responds to replication stress and functions in interstrand cross-link repair. <i>DNA Repair</i> , 2006, 5, 1398-1406.	2.8	60
18	Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scale. <i>Current Opinion in Genetics and Development</i> , 2015, 30, 1-6.	3.3	57

#	ARTICLE	IF	CITATIONS
19	Human SNM1A suppresses the DNA repair defects of yeast <i>pso2</i> mutants. <i>DNA Repair</i> , 2008, 7, 230-238.	2.8	51
20	The MRT-1 nuclease is required for DNA crosslink repair and telomerase activity in vivo in <i>Caenorhabditis elegans</i> . <i>EMBO Journal</i> , 2009, 28, 3549-3563.	7.8	50
21	Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing. <i>Clinical Chemistry</i> , 2018, 64, 1626-1635.	3.2	46
22	Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer. <i>Nature Communications</i> , 2020, 11, 139.	12.8	44
23	The genomic landscape of oesophagogastric junctional adenocarcinoma. <i>Journal of Pathology</i> , 2013, 231, 301-310.	4.5	42
24	<i>C. elegans</i> : A model of Fanconi anemia and ICL repair. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2009, 668, 103-116.	1.0	34
25	<i>Schizosaccharomyces pombe</i> Checkpoint Response to DNA Interstrand Cross-Links. <i>Molecular and Cellular Biology</i> , 2003, 23, 4728-4737.	2.3	33
26	Comprehensive Genomic Analysis of a BRCA2 Deficient Human Pancreatic Cancer. <i>PLoS ONE</i> , 2011, 6, e21639.	2.5	17
27	Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer. <i>Nature Ecology and Evolution</i> , 2021, 5, 1024-1032.	7.8	16
28	BRCA1 ubiquitylation of CtIP: Just the tIP of the iceberg?. <i>DNA Repair</i> , 2006, 5, 1499-1504.	2.8	15
29	Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma. <i>Cancers</i> , 2019, 11, 736.	3.7	15
30	Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes. <i>Journal of the National Cancer Institute</i> , 2021, 113, 88-98.	6.3	15
31	Circulating Tumour DNA Sequencing Identifies a Genetic Resistance-Gap in Colorectal Cancers with Acquired Resistance to EGFR-Antibodies and Chemotherapy. <i>Cancers</i> , 2020, 12, 3736.	3.7	6